Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N(4-hydroxybutyl) nitrosamine

Cancer Research

Volumn 58, Issue 14, 1998, Pages 3028-3031

  Okajima, Eijiro ^a   Denda, Ayumi ^a   Ozono, Seiichiro ^a   Takahama, Makoto ^a   Akai, Hiroyuki ^a   Sasaki, Yasutaka ^a   Kitayama, Wakashi ^a   Wakabayashi, Keiji ^b   Konishi, Yoichi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE; NIMESULIDE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; HISTOPATHOLOGY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; TRANSITIONAL CELL CARCINOMA;

ANIMALS; BODY WEIGHT; BUTYLHYDROXYBUTYLNITROSAMINE; CARCINOGENS; CARCINOMA; CYCLOOXYGENASE INHIBITORS; EATING; INCIDENCE; MALE; ORGAN SIZE; RATS; RATS, INBRED F344; SULFONAMIDES; URINARY BLADDER NEOPLASMS;

EID: 0032528189     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Kelloff, G. J., Boone, C. W., Crowell, J. A., Steele, V. E., Lubet, R., and Sigman, C. C. Chemopreventive drug development: perspectives and progress. Cancer Epidemiol. Biomark. Prev., 3: 85-98, 1994.
2. Giardiello, F. M., Offerhaus, G. J. A., and DuBois, R. N. The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Eur. J. Cancer, 31A: 1071-1076, 1995.
3. Moon, R. C., Detrisac, C. J., Thomas, C. F., and Kelloff, G. J. Chemoprevention of experimental bladder cancer. J. Cell. Biochem. Suppl., 161: 134-138, 1992.
4. Denda, A., Endoh, T., Kitayama, W., Tang, Q., Noguchi, O., Kobayashi, Y., Akai, H., Okajima, E., Tsujiuchi, T., Tsutsumi, M., Nakae, D., and Konishi, Y. Inhibition by piroxicam of oxidative DNA damage, liver cirrhosis and development of enzymealtered nodules caused by a choline-deficient, L-amino acid-defined diet in rats. Carcinogenesis (Lond.), 18: 1921-1930, 1997.
5. Marnett, L. J. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res., 52: 5575-5589, 1992.
6. Lupulescu, A. Prostaglandins, their inhibitors and cancer. Prostaglandins Leukotrienes Essent. Fatty Acids, 54: 83-94, 1996.
7. Hershman, H. R. Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. Cancer Metastasis Rev., 13: 241-256, 1994.
8. Kargman, S. L., O'Neill, G. P., Vickers, P. J., Evans, J. F., Mancini, J. A., and Jothy, S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res., 55: 2556-2559, 1995.
9. DuBois, R. N., Radhika, A., Reddy, B. S., and Entingh, A. J. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonie tumors. Gastroenterology, 110: 1259-1262, 1996.
10. Restimäki, A., Honkanen, N., Jänkälä, H., Sipponen, P., and Härkönen, M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res., 57: 1276-1280, 1997.
11. Müller-Decker, K., Scholz, K., Marks, F., and Fürstenberger, G. Differential expression of prostaglandin H synthase isozymes during multistage carcinogenesis in mouse epidermis. Mol. Carcinogenesis (Lond.), 12: 31-41, 1995.
12. Liu, X-H., and Rose, D. P. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res., 56: 5125-5127, 1996.
13. Tsujii, M., and DuBois, R. N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell, 83: 493-501, 1995.
14. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87: 803-809, 1996.
15. Meade, E. A., Smith, W. L., and DeWitt, D. L. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem., 268: 6610-6614, 1993.
16. Gierse, J. K., Hauser, S. D., Creely, D. P., Koboldt, C., Rangwala, S. H., Isakson, P. C., and Seibert, K. Expression and selective inhibition of the constitutive and inducible forms of human cyclooxygenase. Biochem. J., 305: 479-484, 1995.
17. Reddy, B. S., Rao, C.V., and Seibert, K. Evaluation of cyclooxygenase-2 inhibitor for potential Chemopreventive properties in colon carcinogenesis. Cancer Res., 56: 4566-4569, 1996.
18. Takahashi, M., Fukutake, M., Yokota, S., Ishida, K., Wakabayashi, K., and Sugimura, T. Suppression of azoxymethane-induced aberrant crypt foci in rat colon by nimesulide, a selective inhibitor of cyclooxygenase 2. J. Cancer Res. Clin. Oncol., 122: 219-222, 1996.
19. Nakatsugi, S., Fukutake, M., Takahashi, M., Fukuda, K., Isoi, T., Taniguchi, Y., Sugimura, T., and Wakabayashi, K. Suppression of intestinal polyp development by nimesulide, a selective cyclooxygenase-2 inhibitor, in Min mice. Jpn. J. Cancer Res., 88: 1117-1120, 1997.
20. Davis, R., and Brogden, R. N. Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs, 48: 431-454, 1994.
21. Cipollini, F., Mecozzi, V., and Altilia, F. Endoscopie assessment of the effects of nimesulide on the gastric mucosa: comparison with indomethacin. Curr. Ther. Res., 45: 1042-1048, 1989.
22. Böttcher, I., Schweizer, A., Glatt, M., and Werner, H. A sulphonamido-indanone derivative CGP 28237 (ZK 34228), a novel non-steroidal anti-inflammatory agent without gastro-intestinal ulcerogenicity in rats. Drugs Exp. Clin. Res., 13: 237-245, 1987.
23. Tavares, I. A., Bishai, P. M., and Bennett, A. Activity of nimesulide on constitutive and inducible cyclooxygenases. Arzneim. Forsch., 45: 1093-1095, 1995.
24. Vago, T., Bevilacqua, M., and Norbiato, G. Effects of nimesulide action time dependence on selectivity towards prostaglandin G/H synthase/cyclooxygenase activity. Arzneim. Forsch. Drug Res., 45: 1096-1098, 1996.
25. Kiemeney, L. A. L. M., Witjes, J. A., Heijbroek, R. P., Debruyene, F. M. J., and the Members of the Dutch South-East Urological Group. The clinical epidemiology of superficial bladder cancer. Br. J. Cancer, 67: 806-812, 1993.
26. Moon, R. C., Kelloff, G. J., Detrisac, C. J., Steele, V. E., Thomas, C. F., and Sigman, C. C. Chemoprevention of OH-BBN-induced bladder cancer in mice by piroxicam. Carcinogenesis (Lond.), 14: 1487-1489, 1993.
27. Rao, K. V. N., Detrisac, C. J., Steele, V. E., Hawk, E. T., Kelloff, G. J., and McCormick, D. L. Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis (Lond.), 17: 1435-1438, 1996.
28. Okajima, E., Ozono, S., Endo, T., Majima, T., Tsutsumi, M., Fukuda, T., Akai, H., Denda, A., Hirao, Y., Okajima, E., Nishino, H., Nir, Z., and Konishi, Y. Chemopreventive efficacy of piroxicam administered alone or in combination with lycopene and β-carotene on the development of rat urinary bladder carcinoma after N-butyl-N-(4-hydroxybutyl)nitrosamine treatment. Jpn. J. Cancer Res., 88: 543-552, 1997.
29. Klän, R., Kinspel, H. H., and Meier, T. Acetylsalicylic acid inhibition of N-butyl-(4-hydroxybutyl)nitrosamine-induced bladder carcinogenesis in rats. J. Cancer Res. Clin. Oncol., 119: 482-485, 1993.
30. Holmäng, S., Cano, M., Grenabo, K., Hedelin, H., and Johansson, S. L. Effect of indomethacin on N-[4-(5-nitro-2-furyl)-2-thiazoyl] formamide-induced urinary tract carcinogenesis in male F344 rats. Carcinogenesis (Lond.), 16: 1493-1498, 1995.
31. Cohen, S. M., Hasegawa, R., Sakata, T., and Johansson, S. L. Effect of aspirin on urinary bladder carcinogenesis initiated with N-[4-(5-nitro-2-furyl)-2-thiazoyl]form-amide in rats. Cancer Res., 49: 372-377, 1989.
32. Maggi, C. A., Evangelista, S., Grimaldi, G., Santicioli, P., Giolitti, A., and Meli, A. Evidence for the involvement of arachidonic acid metabolites in spontaneous and drug-induced contractions of rat urinary bladder. J. Pharmacol. Exp. Ther., 230: 500-513, 1984.
33. Sakata, T., Hasegawa, R., Johansson, S. L., Zenser, T. V., and Cohen, S. M. Inhibition by aspirin of N-[4-(5-nitro-2-furyl)-2-thiazoyl] formamide initiation and sodium saccharin promotion of urinary bladder carcinogenesis in male F344 rats. Cancer Res., 46: 3903-3906, 1986.
34. 2 and ascorbic acid synthesis in bladder carcinogenesis. Carcinogenesis (Lond.), 10: 1651-1656, 1989.
35. Shibata, M., Hasegawa, R., Shirai, T., Takesada, Y., and Fukushima, S. Chemoprevention by indomethacin of tumor promotion in a rat urinary bladder carcinogenesis model. Int. J. Cancer, 55: 1011-1017, 1993.
36. Zenser, T. V., Thomas, D. J., Jacob, A. K., and Davis, B. B. Regulation of prostaglandin H synthase activity in dog urothelial cells. J. Cell. Physiol., 150: 214-219, 1992.
37. Kargman, S., Charleson, S., Cartwright, M., Frank, J., Riendeau, D., Mancini, J., Evans, J., and O'Neill, G. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology, 111: 445-454, 1996.
38. Oyasu, R., Iwasaki, T., Matsumoto, M., Hirao, Y., and Tabuchi, Y. Induction of tumors in heterotopic bladder by topical application of N-methyl-N-nitrosourea and N-butyl-N-(3-carboxypropyl)nitrosamine. Cancer Res., 38: 3019-3025, 1978.
39. Ozono, S., Numata, I., and Oyasu, R. Irreversibility of low-grade superficial rat bladder carcinomas. Cancer Res., 44: 4260-4262, 1984.
40. Kurumbail, R. G., Stevens, A. M., Gierse, J. K., McDonald, J. J., Stegman, R. A., Pak, J. Y., Gildehaus, D., Miyashiro, J. M., Penning, T. D., Seibert, K., Isakson, P. C., and Stalling, W. C. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature (Lond.), 384: 644-648, 1996.
41. Said, S. A., and Foda, A. M. Influence of cimetidine on the pharmacokinetics of piroxicam in rat and man. Arzneim. Forsch. Drug Res., 39: 790-792, 1989.
42. Roskos, L. R., and Boudinot, F. D. Effects of dose and sex on the pharmacokinetics of piroxicam in the rat. Biopharmacol. Drug Dispos., 11: 215-225, 1990.
43. Facino, R. M., Carini, M., Aldini, G., Saibene, L., and Morelli, R. Differential inhibition of superoxide, hydroxyl and peroxyl radicals by nimesulide and its main metabolite 4-hydroxynimesulide. Arzneim. Forsch. Drug Res., 45: 1102-1109, 1995.
44. Piazza, G. A., Rahm, A. K., Finn, T. S., Fryer, B. H., Li, H., Stoumen, A. L., Pamukcu, R., and Ahnen, D. J. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res., 57: 2452-2459, 1997.
45. Elder, D. J. E., Hague, A., Hicks, D. J. M., and Paraskeva, C. Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma cell lines. Cancer Res., 56: 2273-2276, 1996.
46. Hara, A., Yoshimi, N., Niwa, M., Ino, N., and Mori, H. Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines. Jpn. J. Cancer Res., 88: 600-604, 1997.